Open AccessAn Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants
Author(s) -
Ankit Das,
Niraja Ranadive,
Manas Kinra,
Madhavan Nampoothiri,
Devinder Arora,
Jayesh Mudgal
Publication year - 2020
Publication title -
current neuropharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.955
H-Index - 73
eISSN - 1875-6190
pISSN - 1570-159X
DOI - 10.2174/1570159x18666200221113842
Subject(s) - medicine , antidepressant , chemotherapy , depression (economics) , mood , cognition , quality of life (healthcare) , adverse effect , mood disorders , affect (linguistics) , anxiety , oncology , bioinformatics , psychiatry , psychology , nursing , communication , biology , economics , macroeconomics
Cognitive impairment is an adverse reaction of cancer chemotherapy and is likely to affect up to 75% of patients during the treatment and 35% of patients experience it for several months after the chemotherapy. Patients manifest symptoms like alteration in working ability, awareness, concentration, visual-verbal memory, attention, executive functions, processing speed, fatigue and behavioural dysfunctions. Post-chemotherapy, cancer survivors have a reduced quality of life due to the symptoms of chemobrain. Apart from this, there are clinical reports which also associate mood disorders, vascular complications, and seizures in some cases. Therefore, the quality of lifestyle of cancer patients/ survivors is severely affected and only worsens due to the absence of any efficacious treatments. With the increase in survivorship, it's vital to identify effective strategies, until then only symptomatic relief for chemobrain can be provided. The depressive symptoms were causally linked to the pathophysiological imbalance between the pro and antiinflammatory cytokines.